nav-left cat-right
cat-right

CytRx Unveils Clinical Development Plan for Pipeli...

Names World-Renowned Cancer Drug Expert Dr. Joseph Rubinfeld as Chief Scientific Advisor LOS ANGELES–(BUSINESS WIRE)–CytRx Corporation (NASDAQ: CYTR) today unveiled its corporate strategy to focus its internal resources on the clinical development of oncology drug candidates tamibarotene and INNO-206, which the Company believes offer the greatest mix of near-term and medium-term...

MorphoSys and Galapagos Enter Alliance to Co-devel...

Combination of Proprietary Drug Targets and Unique Technologies to Create Range of New Therapeutic Antibodies MUNICH, GERMANY — (Marketwire) — 11/26/08 — MorphoSys AG (FSE: MOR; Prime StandardSegment, TecDAX) and Galapagos NV (Euronext: GLPG) announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and...

Trends in Drug Research 27th Noordwijkerhout-Camer...

The Symposium is sponsored by the European Federation of Medicinal Chemistry (EFMC). The Organising and Scientific Committees cordially invite you to attend the 27 edition of this meeting on Trends in Drug Research. The interplay between molecular structure and biological activity is central to contemporary biomedical and translational research, relevant not only to structural biologists but also to diverse scientists...

Company and People Notes: Patheon and Solvias Form...

Nov 20, 2008 ePT–the Electronic Newsletter of Pharmaceutical Technology Company Notes San Jose, CA (Nov. 14)—AnaSpec established a new facility dedicated to peptide production that complies with good manufacturing practice (GMP). The new facility is adjacent to AnaSpec’s headquarters and provides 5000 ft2 of dedicated GMP space, including two Class 10,000 cleanrooms. AnaSpec produces GMP peptides...

Galapagos and Merck Serono Enter New Collaboration...

Mechelen, Belgium; 18 November 2008 – Galapagos NV (Euronext: GLPG) announced today new collaboration agreements with Merck Serono, a division of Merck KGaA, Darmstadt, Germany. Total value of the contracts for Galapagos is €1.1 million over one year. Galapagos’ service division BioFocus DPI will provide SoftFocus© compounds for use in Merck Serono’s drug discovery programs. In a separate...

GEN Reports on the Trend Toward Predictive Toxicog...

NEW ROCHELLE, N.Y., Nov 19, 2008 /PRNewswire via COMTEX/ — Biotech scientists increasingly are applying genomics technologies to toxicology research to better understand the effects of novel drug candidates on a variety of organ systems, reports Genetic Engineering & Biotechnology News (GEN). They are especially interested in figuring out a new compound’s mechanism of action and eventually developing a...
Page 30 of 34« First...1020...2829303132...Last »